Results 41 to 50 of about 127 (117)
Cost-effectiveness thresholds: pros and cons. [PDF]
Bull World Health Organ, 2016 Bertram MY +6 more
europepmc +1 more source
Качественная клиническая практика, 2018 Background. Budget impact analyses (BIAs) are an essential part of a comprehensive economic assessment of a health care intervention and are increasingly required by reimbursement authorities as part of a listing or reimbursement submission.
Sean D. Sullivan +12 more
doaj
Качественная клиническая практика, 2018 Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background ...
Y. I. Ashikhmin, D. Yu. Belousov
doaj
Assessment of the economic efficiency of the anesthetic nefopam in therapy postoperative pain
Качественная клиническая практика, 2018 The purpose of this pharmacoeconomic analysis was to determine the drug Nefopam economic feasibility of its use for postoperative pain relief in terms of the health system of the Russian Federation.
D. Yu. Belousov +2 more
doaj
Budget impact of modern drugs for the treatment of schizophrenia: regional aspects
Качественная клиническая практика, 2018 The article presents the results of comparative pharmacoeconomic analysis of treatment of schizophrenia with antipsychotics of the first and second generation in Khabarovsk territory.
K. V. Krot +2 more
doaj
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia
Качественная клиническая практика, 2018 We conduct a comparative cost-effectiveness and budget impact analysis of atypical antipsychotics for the treatment of schizophrenia - sertindole versus quetiapine, paliperidone. The primary outcome of interest was rehospitalization rates.
I. S. Krysanov, V. Yu. Ermakova
doaj
Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease
Качественная клиническая практика, 2018 Objective. Health economic expertise of pramipexole extended release monotherapy at early stages of Parkinson’s disease. Methods. An economic model was developed based on clinical studies to derive comparative information on the effectiveness, utility ...
D. Yu. Belousov, E. V. Afanasyeva
doaj
Comparative pharmacoeconomical analysis of modern antidepressants in monotherapy
Качественная клиническая практика, 2018 Compare the cost effectiveness and budget impact of vortioxetine in monotherapy of depressive disorders with several other important antidepressants using pharmacoeconomic methods within context of Russian healthcare.
A. E. Cheberda +2 more
doaj
Clinical and economic analysis of biologic drugs in treatment of psoriasis
Качественная клиническая практика, 2018 Purpose. To evaluate the cost effectiveness of use of ustekinumab (Stelara®), infliximab (Remicade®) and adalimumab (Humira®) for treatment of moderate and severe psoriasis. Methods.
A. A. Kubanov +2 more
doaj
Pharmacoeconomic analysis of Cocarnit® complex as treatment for diabetic polyneuropathy
Качественная клиническая практика, 2018 Diabetic polyneuropathy (DP) occupies the third place among the most common neurological disorders, affecting a significant portion of diabetes patients, and is characterized by progressive lesions of nervous fibers.
D. Yu. Belousov, A. E. Cheberda
doaj